Therapeutics case studies

A biotech company sought ICON's help to analyse and report on a limited data set to demonstrate cardiovascular safety in a rare disease study.

A pharmaceutical sponsor contracted ICON to run a phase 3 trial for an amyotrophic lateral sclerosis (ALS) treatment that included a large patient population spanning 14 countries.

ICON partnered with a top biopharma in the clinical development of CAR T for patients with relapsed and/or refractory Multiple Myeloma (BCMA construct) and B-cell Lymphomas (CD19 construct).

A large pharma company was attempting to recruit 50 patients, including 15 treatment-naive patients, in a global study for a rare pulmonary disorder.